PL2606120T4 - Ludzkie komórki ułatwiające tolerancję i ich zastosowanie - Google Patents

Ludzkie komórki ułatwiające tolerancję i ich zastosowanie

Info

Publication number
PL2606120T4
PL2606120T4 PL11818739T PL11818739T PL2606120T4 PL 2606120 T4 PL2606120 T4 PL 2606120T4 PL 11818739 T PL11818739 T PL 11818739T PL 11818739 T PL11818739 T PL 11818739T PL 2606120 T4 PL2606120 T4 PL 2606120T4
Authority
PL
Poland
Prior art keywords
application
human cells
facilitate tolerance
tolerance
facilitate
Prior art date
Application number
PL11818739T
Other languages
English (en)
Other versions
PL2606120T3 (pl
Inventor
Suzanne Ildstad
Mary Jane Elliott
Original Assignee
Univ Louisville Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found Inc filed Critical Univ Louisville Res Found Inc
Publication of PL2606120T4 publication Critical patent/PL2606120T4/pl
Publication of PL2606120T3 publication Critical patent/PL2606120T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
PL11818739T 2010-08-17 2011-08-17 Ludzkie komórki ułatwiające tolerancję i ich zastosowanie PL2606120T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37446010P 2010-08-17 2010-08-17
US12/957,011 US8632768B2 (en) 2008-05-30 2010-11-30 Human facilitating cells
EP11818739.2A EP2606120B1 (en) 2010-08-17 2011-08-17 Human facilitating cells and uses thereof
PCT/US2011/048120 WO2012024427A2 (en) 2010-08-17 2011-08-17 Human facilitating cells and uses thereof

Publications (2)

Publication Number Publication Date
PL2606120T4 true PL2606120T4 (pl) 2016-06-30
PL2606120T3 PL2606120T3 (pl) 2016-06-30

Family

ID=45605659

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11818739T PL2606120T3 (pl) 2010-08-17 2011-08-17 Ludzkie komórki ułatwiające tolerancję i ich zastosowanie

Country Status (14)

Country Link
US (3) US8632768B2 (pl)
EP (2) EP2606120B1 (pl)
JP (2) JP5980783B2 (pl)
CN (2) CN105950556B (pl)
AU (1) AU2011292011B2 (pl)
CA (1) CA2807701C (pl)
DK (1) DK2606120T3 (pl)
ES (1) ES2561087T3 (pl)
HR (1) HRP20160102T1 (pl)
HU (1) HUE028335T2 (pl)
PL (1) PL2606120T3 (pl)
RS (1) RS54549B1 (pl)
SI (1) SI2606120T1 (pl)
WO (1) WO2012024427A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8632768B2 (en) * 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
US11291686B2 (en) 2008-05-30 2022-04-05 University Of Louisville Research Foundation, Inc. Human facilitating cells
ES2588730T3 (es) * 2011-03-17 2016-11-04 Miltenyi Biotec Gmbh Preparados celulares agotados en lo que respecta a TCRalfa/beta
WO2013044029A1 (en) 2011-09-23 2013-03-28 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
MX370404B (es) 2011-12-22 2019-12-11 Yeda Res & Dev Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
US9657290B2 (en) 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
AU2014221330B2 (en) * 2013-02-26 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Combined organ and hematopoietic cells for transplantation tolerance of grafts
RU2020122439A (ru) * 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
CN107532333A (zh) 2015-02-22 2018-01-02 里兰斯坦福初级大学理事会 微筛选装置、方法和产品
JP6733209B2 (ja) * 2015-03-18 2020-07-29 セイコーエプソン株式会社 シート製造装置
CN115254210A (zh) 2016-11-14 2022-11-01 浩康生物系统公司 用于分选目标颗粒的方法和装置
WO2018165161A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods and compositions for determining the potency of a therapeutic cellular composition
EP3595683A1 (en) 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
DK3749334T3 (da) 2018-02-08 2025-02-17 Univ Leland Stanford Junior Allogen hæmatopoietisk stamcelletransplantation
WO2019178106A1 (en) * 2018-03-12 2019-09-19 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
WO2020247341A1 (en) * 2019-06-06 2020-12-10 Medeor Therapeutics, Inc. Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells
US20230201256A1 (en) * 2020-05-21 2023-06-29 Medeor Therapeutics, Inc. Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient
EP4228406A4 (en) * 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
NZ255039A (en) * 1992-07-10 1997-03-24 Univ Pittsburgh Mammalian hematopoietic facilitatory cells and their use in preventing graft-versus-host disease in bone marrow transplants
US5772994A (en) * 1993-05-28 1998-06-30 The University Of Pittsburgh Hematopoietic facilitatory cells and their uses
JPH09508007A (ja) * 1994-01-05 1997-08-19 ユニバーシティー オブ ピッツバーグ 造血増進性細胞により発現された抗原に対するモノクローナル抗体
AU1705599A (en) 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
WO2002040640A2 (en) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
US20040228845A1 (en) * 2003-05-14 2004-11-18 Ildstad Suzanne T. Methods of using CD8+/TCR- facilitating cells (FC) for the engraftment of purified hematopoietic stem cells (HSC)
AU2002309703A1 (en) * 2001-05-09 2002-11-18 The University Of Louisville Research Foundation, Inc. Hematopoietic stem cell chimerism to treat autoimmune disease
US20050118142A1 (en) * 2001-08-01 2005-06-02 Ildstad Suzanne T. Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2005023982A2 (en) 2003-05-28 2005-03-17 Univ. Of Louisville Research Foundation, Inc. Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients
US8632768B2 (en) 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
CA2726341C (en) * 2008-05-30 2018-12-18 University Of Louisville Research Foundation, Inc. Human facilitating cells

Also Published As

Publication number Publication date
HUE028335T2 (en) 2016-12-28
JP2013535230A (ja) 2013-09-12
JP5980783B2 (ja) 2016-08-31
EP3037522A1 (en) 2016-06-29
US9452184B2 (en) 2016-09-27
CN105950556B (zh) 2021-12-03
US8632768B2 (en) 2014-01-21
DK2606120T3 (en) 2016-02-08
US20140134141A1 (en) 2014-05-15
CA2807701C (en) 2023-12-19
WO2012024427A2 (en) 2012-02-23
AU2011292011A1 (en) 2013-02-21
EP2606120B1 (en) 2015-10-28
WO2012024427A3 (en) 2012-05-10
AU2011292011B2 (en) 2015-08-13
HRP20160102T1 (hr) 2016-02-26
JP6449199B2 (ja) 2019-01-09
HK1184488A1 (en) 2014-01-24
CN103328627B (zh) 2016-06-01
EP2606120A2 (en) 2013-06-26
US20110110909A1 (en) 2011-05-12
RS54549B1 (sr) 2016-06-30
ES2561087T3 (es) 2016-02-24
CN105950556A (zh) 2016-09-21
US20170000825A1 (en) 2017-01-05
CN103328627A (zh) 2013-09-25
SI2606120T1 (sl) 2016-03-31
EP2606120A4 (en) 2014-03-26
PL2606120T3 (pl) 2016-06-30
JP2016190866A (ja) 2016-11-10
CA2807701A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
PL2606120T4 (pl) Ludzkie komórki ułatwiające tolerancję i ich zastosowanie
IL254144A0 (en) Methods for reprogramming cells and uses thereof
BR112012031446A2 (pt) componentes e métodos para implantes
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
BR112012027159A2 (pt) estrutura e método
EP2770899A4 (en) TISSUE AND CELLULAR IMAGING
PL2544682T3 (pl) Fitokannabinoidy w leczeniu glejaka
EP2593463A4 (en) FORMULATIONS OF RIFAXIMINE AND APPLICATIONS THEREOF
IL221511A (en) Arilatriazolones associated with bis aryl and their use
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
IL221042A (en) Phospholipid profiling and cancer
ZA201208173B (en) Peptices and their use
BR112013011340A2 (pt) géis e hidro géis
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
IL223667B (en) S100a4 antibodies and therapeutic uses thereof
FR2963612B1 (fr) Element en treillis et grue
BR112013009579A2 (pt) método e comprimido
BR112012027715A2 (pt) método e célula fotovoltaica
DK2753346T3 (da) Ceramidase og celledifferentiering
EP2547464A4 (en) ARRANGEMENT AND VENTILATION ARRANGEMENT
DE11786796T8 (de) Antigenpeptid und verwendung davon
PT2563806E (pt) Leucolectinas humanas e suas utilizações
FR2964937B1 (fr) Triporteur et direction de triporteur
BR112013014915A2 (pt) composição curativa e métodos de tratamento